Physician profile
Bernard M Reen
NPI 1740288042
$3,569.01
in general payments reported to CMS, 2019-2025
20 companies · $54.17 in 2025
The $54.17 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,314 · 2020: $365 · 2021: $594 · 2022: $457 · 2023: $401 · 2024: $384 · 2025: $54.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,167.30 | 2019-2025 | Assurity, Gallant, Jot Dx |
| Boston Scientific Corporation | $568.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $387.49 | 2019-2024 | Farxiga |
| Teleflex LLC | $277.51 | 2023 | Guideliner |
| E.R. Squibb & Sons, L.L.C. | $195.49 | 2019-2021 | |
| Edwards Lifesciences Corporation | $187.44 | 2019-2021 | |
| Cardiovascular Systems INC. | $153.04 | 2019-2023 | Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $141.57 | 2021-2022 | |
| Amgen INC. | $131.16 | 2019-2021 | |
| Abiomed | $85.95 | 2019-2024 | Impella |
| Cardiva Medical, INC. | $71.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.68 | 2021 | |
| Ekos Corporation | $25.80 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.73 | 2019-2024 | Lifevest |
| Kiniksa Pharmaceuticals, Ltd. | $21.42 | 2023 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $20.42 | 2024 | Arcalyst |
| Medtronic, INC. | $18.32 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.18 | 2024 | |
| Asahi Intecc USA, INC. | $15.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Reen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.